AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations
AbbVie's Phase 3 trial for lutikizumab in hidradenitis suppurativa met its primary endpoint but fell short of analyst expectations. The drug showed an 8% placebo-adjusted response rate, below mid-phase data. Analysts have mixed views on its commercial potential. AbbVie plans further studies and combinations with other drugs. Avalo Therapeutics' shares dropped due to perceived overlap with lutikizumab.
How this was made
The 30-second read
Why it matters
The trial's modest efficacy may delay regulatory filing timelines and temper market enthusiasm for AbbVie's pipeline in inflammatory diseases.
Market read
First‑report Phase 3 data for a major biotech asset; likely short‑term price impact on ABBV.
What to watch
Potential combination strategies with ABBV-295 and ABBV-701 could unlock additional value beyond the headline trial data.
Background
The INTREPID Phase 3 trial evaluated lutikizumab in hidradenitis suppurativa, a disease with limited treatment options. Competitors include UCB's Bimzelx and Merck's anti‑TL1A candidate.
Ticker impact
AbbVie reported Phase 3 INTREPID trial results for lutikizumab, showing modest efficacy that fell short of analyst expectations.
likely pressure as the market prices in the disappointing efficacy versus peers
Phase 3 data is a primary disclosure; the modest 8% placebo‑adjusted benefit and analyst comments suggest limited upside and potential short‑term sell‑off.
Market effects
May weigh on other HS drug developers and biotech peers focused on inflammatory skin disorders.
Limited to U.S. and European biotech markets.
Modest, confined to specialty pharma space.
Counterpoint
Bullish investors could view the eight secondary endpoints and safety profile as a foundation for future approvals.
Key entities
- companyAbbVie
Pharmaceutical company reporting Phase 3 data.
- druglutikizumab
IL‑1α/β inhibitor under investigation for hidradenitis suppurativa.
